{"id":"NCT00168337","sponsor":"Allergan","briefTitle":"A Study of the Safety and Efficacy of a New Treatment for Diabetic Macular Edema","officialTitle":null,"status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-05","primaryCompletion":"2012-05","completion":"2012-05","firstPosted":"2005-09-15","resultsPosted":"2014-08-04","lastUpdate":"2014-08-04"},"enrollment":554,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetic Macular Edema"],"interventions":[{"type":"DRUG","name":"Dexamethasone","otherNames":["Posurdex®","Ozurdex®"]},{"type":"OTHER","name":"Sham","otherNames":[]}],"arms":[{"label":"Dexamethasone 700 μg","type":"EXPERIMENTAL"},{"label":"Dexamethasone 350 μg","type":"EXPERIMENTAL"},{"label":"Sham","type":"SHAM_COMPARATOR"}],"summary":"This study will evaluate the safety and efficacy of an intravitreal implant of dexamethasone for the treatment of diabetic macular edema.","primaryOutcome":{"measure":"Percentage of Patients With a Best Corrected Visual Acuity (BCVA) Improvement of ≥15 Letters From Baseline in the Study Eye","timeFrame":"Baseline, Month 39/Final Visit","effectByArm":[{"arm":"Dexamethasone 700 μg","deltaMin":22.3,"sd":null},{"arm":"Dexamethasone 350 μg","deltaMin":18.2,"sd":null},{"arm":"Sham","deltaMin":10.8,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":6},"locations":{"siteCount":14,"countries":["United States","Brazil","Canada","Colombia","France","Hungary","India","Italy","New Zealand","Poland","Singapore","South Korea","Taiwan","United Kingdom"]},"refs":{"pmids":["40688490","40634898","33206392","31654188","26581718","26519345"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":63,"n":187},"commonTop":["Cataract","Intraocular Pressure Increased","Conjunctival Haemorrhage","Hypertension","Vitreous Haemorrhage"]}}